-Newsclick.in A few weeks back Fortune magazine and CNN carried a long online blog titled ‘Dirty Medicine' by Dinesh Thakur, a former employ of Ranbaxy, where he recounts how he came across several procedural and other lapses in the company's manufacturing facilities. Since then the Fortune blog has become one of the most widely circulated and commented upon business stories in the world. The story received attention as it came in the...

-The Hindu     Restrictions on cross-media ownership in offing too The Telecom Regulatory Authority of India (TRAI) is all set to recommend the creation of an ‘institutional buffer between corporate owners and newspaper management' to the government. TRAI, which is also the regulator for the broadcasting industry, will also suggest ways to restrict cross-media ownership in line with practices in ‘most other established democracies.' TRAI chairman Rahul Khullar told The Hindu his recommendations would...

-Tehelka.com There are few figures from the adivasi community in India who have made a bigger dent in the collective imagination of the country than Dayamani Barla. The "iron lady of Jharkhand" has been instrumental in articulating adivasi struggles against displacement and deprivation on national and international platforms. Dayamani, who was recently imprisoned in Jharkhand for her involvement in the Nagri people's movement, has won the first Ellen L Lutz Indigenous...

-Outlook The Maoists want a military conflict as it brings more adivasis into their fold. The Indian state's best bet is in ensuring that it wins over the aam adivasis to its side.   May 25th's condemnable attack by the People's Liberation Guerrilla Army, which ended up killing and injuring over 50 people from Congress politicians to migrant adivasi labourers, cannot be understood without recognising the Maoist party's explicit political aims. These...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...